Table 1. Patient characteristics of study population (n=81).
| Characteristic | Frequency (%) |
|---|---|
| Age | |
| ≤50 years | 30 (37.0) |
| >50 years | 51 (63.0) |
| Sex | |
| Male | 38 (46.9) |
| Female | 43 (53.1) |
| Performance status | |
| ECOG 1 | 52 (64.2) |
| ECOG 2 | 29 (35.8) |
| Clinical stage | |
| II (high risk) | 50 (61.7) |
| III | 31 (38.3) |
| T stage (tumor invasion) | |
| T2–3 | 49 (60.5) |
| T4 | 28 (34.6) |
| Missing | 4 (4.9) |
| Nodes removed | |
| <10 | 58 (71.6) |
| ≥10 | 8 (9.9) |
| Missing | 15 (18.5) |
| Histological grade | |
| Well differentiated tumor | 37 (45.7) |
| Moderately-poorly differentiated tumor | 29 (35.8) |
| Missing | 15 (18.5) |
| Adjuvant chemotherapy regimen | |
| FOLFOX | 11 (13.6) |
| CAPOX | 70 (86.4) |
| Time to start of treatment | |
| ≥7 weeks | 31 (38.3) |
| <7 weeks | 45 (55.6) |
| Missing | 5 (6.2) |
| Cycles of regimen | |
| FOLFOX (n=11) | |
| <10 cycles | 6 (54.5) |
| ≥10 cycles | 5 (45.5) |
| CAPOX (n=70) | |
| <6 cycles | 11 (15.7) |
| ≥6 cycles | 58 (82.9) |
| Missing | 1 (1.4) |
| Oxaliplatin dose used | |
| FOLFOX (n=11) | |
| 85 mg | 11 [100] |
| CAPOX (n=70) | |
| 85–115 mg | 16 (22.9) |
| 120–140 mg | 54 (77.1) |